{"id":970629,"date":"2026-06-04T08:47:45","date_gmt":"2026-06-04T12:47:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/"},"modified":"2026-06-04T08:47:45","modified_gmt":"2026-06-04T12:47:45","slug":"moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/","title":{"rendered":"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>&#8211; Access the segment <\/i><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m3wvkghcJspr424sMTW5PyO_mO_W69Kzvf8P6gK7hkMRSxjgV8Zwd3iomNTJU5yoU3n-pcVZWzfJHwYOognGD67MrwE78eAHxmL5WI0UCHo=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <i>here<\/i><br \/>\n        <\/a><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <b>HOUSTON, June  04, 2026  (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc.<\/b>, (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vcql5BjsEzpigwdxjvW8ZDYrMcMk90phQbNiLmCsW3b4QWqyoEt4AylXFw5XAdt3rgQLUJMZeFnrFkxkM8Tex3hCgYfg2bIYmvj4CojOrH18_fLlcoFQIqszZBXzTj6qmoqeYy0eo1slFxG96mYPvQ==\" rel=\"nofollow\" target=\"_blank\">Virtual Investor \u201cWhat This Means\u201d segment<\/a>.<\/p>\n<p align=\"justify\">As part of the segment, Mr. Klemp discussed the Company\u2019s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B\/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R\/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation for the trial\u2019s interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.<\/p>\n<p align=\"justify\">The segment is now available for on-demand viewing <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m3wvkghcJspr424sMTW5P7DSIkKN3l3IUI6lekSfHBz-3yZaJ1qQdhDORjGwj3kkVjAioom4_APyEbsc4wbEjyUWsr4aeM4gt-nBt7XGNw8=\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p>\n        <b>About Moleculin Biotech, Inc.<\/b>\n      <\/p>\n<p align=\"justify\">Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company\u2019s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.<\/p>\n<p align=\"justify\">The Company has begun the MIRACLE (<b>M<\/b>olecul<b>i<\/b>n\u00a0<b>R<\/b>\/R AML\u00a0<b>A<\/b>nnAraC\u00a0<b>Cl<\/b>inical\u00a0<b>E<\/b>valuation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as \u201cAra-C\u201d) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B\/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.<\/p>\n<p align=\"justify\">Additionally, the Company is developing WP1066, an Immune\/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.\u00a0<\/p>\n<p align=\"justify\">For more information about the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p574KX2SQIb2MDrmTMmUbLhqjajEZBD_wNU12Qe6USIcGaFXE-OuhqMhj0BZLY7n9iWh35ieZyDu86YO_9m1yML_qED64PFAYgyg28j7Jos=\" rel=\"nofollow\" target=\"_blank\">www.moleculin.com<\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=caH2m4dSr1aIIqDA06KR0G_gbHk8941m5yUlp7ZAv8eV46dxDiDTb6d14lc7xBSX4IA1QWjWI5buOru7KV1tzg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9QADdf797Q7NdxVNLERZl9BLXZNoC9PISZCAnsmg4QiZXIdncGEQh-x6xCi_X44INywgv7y11hjxQqDzudcRVC36uf1PCwzH6aLQegN2YgGLb2tKcjbT-azs0EPj12hE\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KHYHkLWBAkQwkGt4ZoBO4VpVmiiTWPgo6J02qaaie7wPN78wTRJ-bYzG3W5ArE05BpWtoATllrwIWFA42hY5R0LdOTShq95aYWscEenAQO8=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-Looking Statements<\/b><br \/>\n        <br \/>Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the expected timing and results of the 45-subject interim data unblinding in the MIRACLE trial, the anticipated clinical milestones set forth above, and the potential efficacy and safety of Annamycin and AnnAraC in R\/R AML and other indications. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company\u2019s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including \u2018believes,\u2019 \u2018estimates,\u2019 \u2018anticipates,\u2019 \u2018expects,\u2019 \u2018plans,\u2019 \u2018projects,\u2019 \u2018intends,\u2019 \u2018potential,\u2019 \u2018may,\u2019 \u2018could,\u2019 \u2018might,\u2019 \u2018will,\u2019 \u2018should,\u2019 \u2018approximately\u2019 or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. \u201cRisk Factors\u201d in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.<\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(908) 824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EOOpISuCMZy5N-GLcgpd8yNx06r6NkF3II7QKV34TWglK_WigK_3AA_gTkr7tcsKHA5Nw0wmYYh7WQtvT524FA==\" rel=\"nofollow\" target=\"_blank\">MBRX@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjE2MzgyZTQtNTVhNS00OWUzLTk5MDktZDBlMTU0NDVlN2VhLTUwMDEzMzYwNy0yMDI2LTA2LTA0LWVu\/tiny\/Moleculin-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor \u201cWhat This Means\u201d segment. As part of the segment, Mr. Klemp discussed the Company\u2019s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B\/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R\/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation for the trial\u2019s interim 45 subject data unblinding, which remains on track for mid-2026 and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970629","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor \u201cWhat This Means\u201d segment. As part of the segment, Mr. Klemp discussed the Company\u2019s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B\/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R\/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation for the trial\u2019s interim 45 subject data unblinding, which remains on track for mid-2026 and &hellip; Continue reading &quot;Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T12:47:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment\",\"datePublished\":\"2026-06-04T12:47:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/\"},\"wordCount\":794,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/\",\"name\":\"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==\",\"datePublished\":\"2026-06-04T12:47:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/","og_locale":"en_US","og_type":"article","og_title":"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk","og_description":"&#8211; Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor \u201cWhat This Means\u201d segment. As part of the segment, Mr. Klemp discussed the Company\u2019s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B\/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R\/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation for the trial\u2019s interim 45 subject data unblinding, which remains on track for mid-2026 and &hellip; Continue reading \"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-04T12:47:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment","datePublished":"2026-06-04T12:47:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/"},"wordCount":794,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/","name":"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==","datePublished":"2026-06-04T12:47:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTg0MyM3NjM2NTgzIzUwMDEzMzYwNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-ceo-walter-klemp-highlights-45-subject-enrollment-milestone-in-recent-virtual-investor-what-this-means-segment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor \u201cWhat This Means\u201d Segment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970629"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}